India Pharma Outlook Team | Tuesday, 14 October 2025
Pfizer Inc. will be presenting the latest developments of their infectious disease portfolio at IDWeek 2025 from October 19-22, 2025. The company will share results across 46 abstracts, comprising both company- and collaborator-led studies.
“IDWeek 2025 is a turning point for us to present to the public our most recent scientific progress and connect with the global experts in the battle against infectious diseases,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer. “We are dedicated to innovation and the generation of clinical and real-world evidence through our infectious disease portfolio.”
Among the presentations will be studies of the infectious diseases mentioned above (e.g., COVID-19), respiratory syncytial virus (RSV), pneumococcal disease, Lyme disease, meningococcal disease, as well as other serious bacterial and viral infections.
In addition to the oral presentations, poster presentations will provide information on Pfizer’s wide-ranging portfolio. This will help to illustrate how the company’s science-driven approach is meeting the unmet medical needs and improving patient outcomes worldwide.
Also Read: Bristol Myers Squibb Launches Kopozgo for oHCM in India
Grounded in science and employing the most comprehensive resources worldwide, Pfizer’s goal is to be the most successful company at bringing innovative therapies to market that have a great impact on patients' lives.
IDWeek 2025 will be the occasion to do so, among many other important moments, to renew synergies with other key healthcare professionals and help research be translated into practical clinical interventions much faster and in more parts of the world.
